TriangleIsatuximab (NCT05344833)
Isatuximab trial for Multiple Myeloma (NCT05344833). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients older than 18 with multiple myeloma and detectable residual disease after autologous transplantation, following at most two prior treatment lines.
The idea: intravenous isatuximab targets CD38 on myeloma cells, alongside oral lenalidomide. Maintenance starts before day 180 after transplant; marrow tests track residual disease. Isatuximab dosing becomes less frequent. Researchers assess complete responses with undetectable residual disease at one year. Patients resistant to anti-CD38 drugs or lenalidomide are excluded.
This phase 2 study plans 50 patients. University of Illinois Chicago sponsors it; two US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.